HIV vaccine development: The myth of Sisyphus modernized?

Expert Review of Vaccines

Volumn 6, Issue 6, 2007, Pages 879-882

  Ljungberg, Karl ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DEVELOPING COUNTRY; DISEASE COURSE; EDITORIAL; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; PRIORITY JOURNAL; PROSTITUTION; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; HIV INFECTIONS; HUMANS; MYTHOLOGY; TECHNOLOGY, PHARMACEUTICAL;

EID: 37149034310     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.6.6.879     Document Type: Editorial

References (24)

1. UNAIDS/WHO. AIDS Epidemic Update: December, UNAIDS/WHO (2006).
2. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl Acad. Sci. USA 96, 10958-10961 (1999).
3. Anastassopoulou CG, Kostrikis LG. Global genetic variation of HIV-1 infection. Curr. HIV Res. 4, 365-373 (2006).
4. Villinger F, Brar SS, Brice GT et al. Immune and hematopoietic parameters in HIV-1-infected chimpanzees during clinical progression toward AIDS. J. Med. Primatol. 26, 11-18 (1997).
5. Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J. Intern. Med. 262, 44-58 (2007).
6. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N. Engl. J. Med. 356, 2073-2081 (2007).
7. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665 (2005).
8. Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
9. McMichael AJ. HIV. The immune response. Curr. Opin. Immunol. 8, 537-539 (1996).
10. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature 410, 980-987 (2001).
11. Ogg GS, Jin X, Bonhoeffer S et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103-2106 (1998).
12. Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
13. Barouch DH, Santra S, Schmitz JE et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
14. Barouch DH, Kunstman J, Kuroda MJ et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339 (2002).
15. Feeney ME, Tang Y, Roosevelt KA et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J. Virol. 78, 8927-8930 (2004).
16. Goulder PJ, Phillips RE, Colbert RA et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3, 212-217 (1997).
17. Crooks ET, Moore PL, Franti M et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366(2), 245-262 (2007).
18. Dey AK, David KB, Klasse PJ, Moore JP. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology 360, 199-208 (2007).
19. Yuan W, Bazick J, Sodroski J. Characterization of the multiple conformational states of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J. Virol. 80, 6725-6737 (2006).
20. 1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6, 200-206 (2000).
21. Emini EA, Schleif WA, Nunberg JH et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730 (1992).
22. Parren PW, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340-8347 (2001).
23. Baeten JM, Overbaugh J. Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr. HIV Res. 1, 69-86 (2003).
24. Chan DJ. Fatal attraction: sex, sexually transmitted infections and HIV-1. Int. J. STD AIDS 17, 643-651 (2006).